Clinical Scorecard: AHA Issues Pediatric Hypertriglyceridemia Statement
At a Glance
Category
Detail
Condition
Pediatric Hypertriglyceridemia
Key Mechanisms
Linked to obesity, insulin resistance, and steatotic liver disease; severe elevations increase risk of acute pancreatitis and atherosclerotic cardiovascular disease.
Target Population
Children and adolescents, particularly those with obesity or elevated body mass index.
Care Setting
Primary care and pediatric settings.
Key Highlights
Affects 10% to 20% of US children and adolescents.
Triglyceride levels classified from acceptable to very severely elevated.
Lifestyle modification is first-line therapy for persistent hypertriglyceridemia.
Pharmacotherapy may be considered for triglyceride levels 400 mg/dL or higher.
Universal cholesterol screening recommended at ages 9-11 and 17-21.
Guideline-Based Recommendations
Diagnosis
Universal cholesterol screening at ages 9-11 and 17-21.
Selective screening for youths with obesity, kidney disease, diabetes, or hypertension.
Management
Lifestyle modification as first-line therapy.
Dietary recommendations include reducing refined carbohydrates and increasing physical activity.
Monitoring & Follow-up
Fasting triglyceride levels are preferred for treatment decisions.
Risks
Severe elevations (above 885 mg/dL) increase risk of acute pancreatitis.
Long-term exposure may increase risk of atherosclerotic cardiovascular disease.
Patient & Prescribing Data
Youths with triglyceride levels 400 mg/dL or higher or primary genetic disorders.
Pharmacotherapy options include omega-3 fatty acids, fenofibrate, and statins for those aged 8 years or older.
Clinical Best Practices
Implement early detection and lifestyle strategies for mild and moderate hypertriglyceridemia.
Consider pharmacotherapy rarely, primarily for severe cases or genetic disorders.
